Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes

Objective:  To quantify adverse events (AEs) associated with the use of metformin (MET), sulphonylureas (SUs) and thiazolidinediones (TZDs) in a usual care setting, and to assess the relationship of AEs to treatment patterns and glycaemic response in patients with type 2 diabetes.

[1]  P. Cryer.  Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes , 2007, Diabetes Care.

[2]  D. Sclar,et al.  Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States, 1990-2001 , 2006, The Diabetes educator.

[3]  T. Finucane.  The dogma of "tight control": beyond the limits of evidence. , 2006, Archives of internal medicine.

[4]  Tao Fan,et al.  Ethnic Disparities and Trends in Glycemic Control Among Adults With Type 2 Diabetes in the U.S. From 1988 to 2002 A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.

[5]  R. Urquhart,et al.  Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. , 2005, Diabetes research and clinical practice.

[6]  M. Hanefeld,et al.  A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[7]  K. Fujioka,et al.  Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studies , 2005, Diabetes, obesity & metabolism.

[8]  S. Mudaliar,et al.  Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[9]  A. Garber,et al.  Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[10]  H. Lochnan,et al.  A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. , 2003, Clinical therapeutics.

[11]  D. Nathan.  Initial Management of Glycemia in Type 2 Diabetes Mellitus , 2002 .

[12]  A. Garber,et al.  Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes , 2002, Diabetes, obesity & metabolism.

[13]  S. Inzucchi.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[14]  J. Wogen,et al.  Utilization of oral hypoglycemic agents in a drug-insured U.S. population. , 2001, Diabetes care.

[15]  G. Grunberger,et al.  Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. , 2001, Diabetes care.

[16]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[17]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[18]  A. Garber,et al.  Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. , 1997, The American journal of medicine.

[19]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[20]  S. Bowlin,et al.  Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. , 2004, Diabetes care.

[21]  H. Lebovitz,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes , 1999 .